Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Key challenges in immunotherapy for AML

Anthony Stein • 3 Jun 2023
ASCO 2023
Acute Myeloid Leukemia Leukemia Antibodies CAR-T NK-Cell Therapy

Anthony Stein, MD, City Of Hope, Duarte, CA, discusses important advances and hurdles in immunotherapy for acute myeloid leukemia (AML), commenting on targeting CD47, the need to find novel treatment targets, and challenges in toxicity with CAR-T and NK-cell therapies for AML. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anthony Stein

3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
0:59
The common clinical manifestations of BPDCN
Anthony Stein • 15 Apr 2024
1:25
Preclinical safety and efficacy of CD123-NK cell engager in R/R AML
Anthony Stein • 3 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals